Proof of Concept (Bone Resorption/Bone Mineral Density) Study

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp. Identifier:
First received: September 19, 2007
Last updated: September 25, 2007
Last verified: September 2007

A study to asses the safety and efficacy of MK0429 in postmenapausal women with osteoporosis.

Condition Intervention Phase
Post-Menopausal Osteoporosis
Drug: MK0429
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Study Start Date: April 2001
Study Completion Date: April 2001

Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Person is a women with osteoporosis who is unwilling or unable to take other treatments for osteoporosis

Exclusion Criteria:

  • Person has had a previous fracture
  • Person has rheumatiod arthritis. Person has has certian types of cancer
  • Person has donated blood or has been in another investigational study within the last 4 weeks
  Contacts and Locations
Please refer to this study by its identifier: NCT00533650

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided Identifier: NCT00533650     History of Changes
Other Study ID Numbers: 2007_620
Study First Received: September 19, 2007
Last Updated: September 25, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases processed this record on April 20, 2014